Gel for Early Hypoglycaemia Prevention in Preterm Infants (GEHPPI)

Oral Dextrose Gel to Prevent Early Hypoglycaemia in Very Preterm Infants

The GEHPPI study is a multicentre placebo controlled randomized controlled trial that aims to prevent early hypoglycaemia in preterm newborns born at ≤32 week's gestation. To do this we will prophylactically administer to these newborns either a small amount of dextrose 40% gel early as possible after birth via the buccal route in the delivery room or a placebo. We hope this dextrose gel will prevent hypoglycemia occurring during the time period needed for the newborns to be transported to the neonatal unit where they will have their venous access inserted.

This trial aims to demonstrate that administering dextrose gel via the buccal route is a simple and rapid method of preventing early hypoglycaemia in this vulnerable patient group.

This trial aims to show that giving dextrose gel via the buccal route is simple and feasible in this premature population.

This trial aims to reduce the need for rescue intravenous dextrose (2ml/kg dextrose 10%) in those babies who are hypoglycaemic at the time of obtaining intravenous access.

Study Overview

• Status: Recruiting
• Conditions: Hypoglycemia in Newborn Infants
• Intervention / Treatment: Dietary supplement: 40% Dextrose Gel; Dietary supplement: 2% carboxymethylcellulose gel

Detailed Description

Fetal glucose homeostasis in-utero has some very important characteristics: Kalhan et al. showed that from 20 weeks gestation onwards the lower limit for in-utero (foetal) glucose was 3 mmol/L over most of their remaining gestation (Kalhan et al., 1979); Secondly, foetal glucose control in-utero is completely dependent on maternal plasma glucose control and maternal insulin secretion (Stanley et al., 2015); Lastly, steady state glucose utilization rates in term neonates are 4 to 6 mg/min/kg, however at earlier gestational ages (both foetal and preterm infants) these values are higher 8-9 mg/min/kg (Hay, 2006) indicating that preterm infants need an early and reliable glucose source at birth.

A local retrospective audit in our Level 3 Neonatal Unit (King et al., 2018) reviewed 90 patients who were born in-house ≤ 32 weeks gestation with birth weight ≤1500g over 12months in CWIUH (April 2016 - March 2017). Analysis showed that the first blood gas (at the time of first intravenous insertion) was at median 48mins (IQR 15min) life. Data showed that 30 of 90 patients (33.3%) had hypoglycaemia of <1.8 mmol/L at the time of first intravenous access. This hypoglycaemia is at a level below an operational threshold (level at which to intervene) most commonly accepted internationally.

Recommendations from the Pediatric Endocrine Society (2015) are that for high-risk neonates (without a suspected congenital hypoglycaemia disorder), the goal of treatment is to maintain a plasma glucose concentration >2.8 mmol/L for those aged < 48hrs (grade 2+ evidence) (Thornton et al., 2015). However the American Academy of Pediatrics Committee on Fetus and Newborn advise that if asymptomatic, intravenous treatment of hypoglycaemia is not needed until glucose concentrations are < 1.4 mmol/L (within 4hrs after birth) or <2.0 mmol/L (from 4 to 24 h after birth) (Adamkin, 2011). However if symptomatic and blood glucose <2.2 mmol/L they recommend treating immediately (Adamkin, 2011).

Regarding long-term outcomes, in 2006 Boluyt et al. performed the first systematic review of the evidence for neurodevelopmental impairment following hypoglycaemia in the first week of life. They felt that none of the 18 eligible studies identified provided a valid estimate of the effect of neonatal hypoglycaemia on neurodevelopment. The authors provided recommendations about an optimal study design (Boluyt et al., 2006). In 2018 Shah et al. performed a systematic review and meta-analysis which included neonates born ≥32 weeks gestation who had been screened for hypoglycaemia in the 1st week of life. The authors felt that tests of general development in infancy are unlikely to adequately assess the effects of neonatal hypoglycaemia on brain development, but instead future studies will require longer-term end points at least into mid-childhood, including specific tests of visual-motor and executive function (Shah et al., 2018).

Despite the absence of consensus in the medical literature today, this study's investigators feel that tackling the problem of early hypoglycaemia in these very/extremely premature infants will allow a smoother transition from in-utero (foetal) to postnatal (ex-utero) glucose homeostasis. This may have important long-term neurodevelopmental consequences.

Our study aims to tackle this problem of early hypoglycemia in these vulnerable newborns. To do this we will give these newborns a small amount of 40% dextrose gel as early as possible after birth via the buccal route. They will absorb the gel through the small blood vessels located on the inside of their cheeks & gums and it will enter their bloodstream quickly. We hope this gel will prevent hypoglycemia occurring during the time period needed for the newborns to be transported to the neonatal unit where they will have some form of venous access inserted.

As this research is a trial we want to see if this dextrose gel has this beneficial effect or not. To do this we need to compare the dextrose gel to a non-sugar containing gel (called the "placebo"). The placebo gel will contain simple cellulose ingredient but does not contain sugar and will have no effect on blood glucose. Both gels used in the trial will look identical in appearance and neither the researcher nor the patient (nor parent/s) will know whether they received either the dextrose or the placebo gels. Which gel a newborn receives will be assigned at random, immediately prior to the birth. All newborns will be cared for in the same way according to best standard care.

Newborns will not undergo any additional tests as part of the study. Blood glucose levels will be measured as per standard practice at the time vascular access is obtained. Blood glucose values will be measured on either a blood gas analyzer or laboratory glucose. Patient data collected as part of the study will be pseudo-anonymized/ anonymized and stored safely. Consent for participation can be withdrawn at any time.

• Study Type: Interventional
• Enrollment (Anticipated): 534
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: John P Kelleher, MB BCH MSPH; Phone Number: 5244 353-1-4085200; Email: jkelleher@coombe.ie
• Study Contact Backup: Name: Julie Sloan; Phone Number: 5244 353-1-4085200; Email: jsloan@coombe.ie

Study Locations

• Czechia
  • Praha, Czechia, Praha 5
    • Recruiting
    • University Hospital Motol
    • Contact: Jan Janota, PhD; Phone Number: 420-603587632; Email: janjanota@yahoo.com
• Ireland
  • Dublin, Ireland, D01P5W9
    • Recruiting
    • Rotunda Hospital
    • Contact: Margaret Moran, MB BCh BAO; Phone Number: 01-8730700; Email: mmoran@rotunda.ie
    • Contact: Christine McDermott, MSc RNP; Phone Number: 01-8730700; Email: cmcdermott@rotunda.ie
  • Dublin, Ireland, D02YH21
    • Recruiting
    • The National Maternity Hospital
    • Contact: Jyothsna Purna, MBBS MRCPCH; Phone Number: 3438 01- 6373100; Email: jpurna@nmh.ie
    • Contact: Shirley Moore, MSc, H. Dip; Phone Number: 01-6373100; Email: shirley.moore@nmh.ie
  • Dublin, Ireland, Dublin 8
    • Recruiting
    • Coombe Women & Infants University Hospital
    • Contact: Julie Sloan; Phone Number: 5244 353-1-4085200; Email: jsloan@coombe.ie
    • Contact: John Kelleher, MB BCh MSPH; Phone Number: 5244 353-1-4085200; Email: jkelleher@coombe.ie
  • Galway, Ireland, XXXXX
    • Recruiting
    • Galway University Hospital
    • Contact: Johannes B Letshwiti, MB BCH; Phone Number: 353-91893678; Email: Johannes.letshwiti@hse.ie
    • Contact: Jean James, RM ANP; Phone Number: 353-91893225; Email: jean.james@hse.ie

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: No older than 3 years (Child)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• The study population will consist of infants born at ≤ 32 weeks gestation. These may include singleton or multiples births.

Exclusion Criteria:

• Any newborn where comfort care (palliative approach) is planned for the care of the newborn following delivery. This will often be due to an antenatally diagnosed lethal and/or major congenital anomaly.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Dextrose Gel; Dextrose 40% gel will be given immediately following stabilization at birth via massage into the buccal membrane. This will be prior to transport from the Delivery Room to the Neonatal Unit. A dose of 1 ml of gel (Dextrose) will be administered to infants born greater than or equal to 29+1 weeks gestation. Prior to administration, a single brief oral suction will be given if required. Half the dose of gel (0.5 ml) will be squeezed onto the gloved finger of a person. This half dose will be given on one side of mouth. The remaining half dose (0.5 ml) of gel will be administered to the other side of the mouth. A total dose of 0.5 ml of gel (Dextrose) will be administered to infants born less than or equal to 29+0 weeks gestation. Half the dose of gel (0.25 ml) will be squeezed onto the gloved finger of administering person. This half dose will be given on one side of mouth. The remaining half dose (0.25 ml) of gel will be administered to the other side of the mouth.	Dietary supplement: 40% Dextrose Gel; Prophylactic administration of 40% dextrose gel via buccal mucosa to prevent newborn hypoglycemia
Placebo Comparator: Placebo; 2% carboxymethylcellulose gel will be given following stabilization at birth via buccal route. This will be prior to in-house transport from the Delivery Room to the Neonatal Unit. A standard total dose of 1 ml of placebo gel will be administered to infants born greater than or equal to 29+1 weeks gestation. Prior to administration, a single brief oral suction will be given if required. Half the dose of gel (0.5 ml) will be squeezed onto the gloved finger of person. This half dose will be given on one side of mouth. The remaining half dose (0.5 ml) of gel will be administered to the other side of the mouth. A total dose of 0.5 ml of gel (Placebo) will be administered to infants born less than or equal to 29+0 weeks gestation. Half the dose of gel (0.25 ml) will be squeezed onto the gloved finger of a person. This half dose will be given on one side of mouth. The remaining half dose (0.25 ml) of gel will be administered to the other side of the mouth.	Dietary supplement: 2% carboxymethylcellulose gel; placebo

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Proportion of newborns with initial hypoglycemia after birth	Proportion of newborns with an initial plasma glucose value below the operational threshold (<1.8 mmol/L) (32.4 mg/dl)(measured on blood gas machine or laboratory sample) at a time-point when initial intravascular access is successfully obtained by the clinical team	30-60 minutes after birth

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Proportion of newborns with a hypoglycaemia episode < 2.6mmol/L (46 mg/dl) within first 24hrs after birth	Any hypoglycemic episode < 2.6 mmol/l (46/mg/dl) within first 24 hours after birth	24 hours after birth
Proportion of newborns with a hypoglycaemia episode <1.8mmol/L (32.4 mg/dl) within first 24hrs after birth	Any hypoglycaemia episode <1.8mmol/L (32.4 mg/dl) within first 24hrs after birth	24 hours after birth
Number of episodes of hypoglycaemia <2.6mmol/L (46 mg/dl) within first 24hrs after birth	Number of episodes of hypoglycaemia <2.6mmol/L (46 mg/dl) within first 24hrs after birth	24 hours after birth
Proportion of newborns with a hyperglycaemia episode > 10 mmol/L (180 mg/dl) within first 24hrs after birth	Proportion of newborns with a hyperglycaemia episode > 10 mmol/L (180 mg/dl) within first 24hrs after birth	24 hours after birth
Proportion of newborns who received rescue IV dextrose within first 24hrs after birth	Number of subjects who received rescue IV dextrose (2ml/kg of Dextrose 10%) within first 24hrs after birth	24 hours after birth
Tolerance of buccal gel in delivery room	Tolerance of buccal gel (dextrose/placebo): as defined by small/moderate/large spills from the mouth of the newborn	30 minutes after birth
Incidence of symptomatic hypoglycaemia	This is defined by a modified Whipples Triad: (1) Presence of characteristic clinical manifestations (tremor, lethargy, coma, seizures) (2) coincident with low plasma glucose concentrations measured accurately with sensitive and precise methods, and (3) that the clinical signs resolve within minutes to hours once normoglycaemia has been re-established.	24 hours after birth
Proportion of newborns who died within the first 12 hours after birth	Proportion of newborns who died due to any etiology within the first 12 hours after birth	12 hours after birth
Proportion of newborns who died after 12 hours following birth but prior to discharge home	Proportion of newborns who died due to any etiology after 12 hours following birth but prior to discharge home or transfer to another hospital	6 months
Incidence of early bacterial sepsis and/or meningitis	Incidence of early bacterial sepsis and/or meningitis. This is defined as a positive bacterial growth in either blood and/or cerebrospinal fluid anytime during first 3 days after birth.	First 3 days after birth
Incidence of necrotising enterocolitis (NEC).	Incidence of NEC prior to discharge home or transfer to another hospital. NEC will be defined at either surgery, at post-mortem, or clinically and radiographically.	6 months
Proportion of newborns with severe retinopathy of prematurity requiring treatment.	Proportion of newborns with severe retinopathy of prematurity requiring treatment. with either Bevacizumab (Avastin) and/or laser therapy. This will be prior to discharge home and/or transfer to another hospital.	6 months
Proportion of newborns with severe (grade III/IV) intraventricular-germinal matrix hemorrhage (IVH-GMH).	Proportion of newborns with severe (grade III/IV) intraventricular-germinal matrix hemorrhage (IVH-GMH). This will be based upon any cranial ultrasound performed prior to discharge or transfer to another hospital.	6 months
Proportion of newborns with periventricular leukomalacia (PVL).	Proportion of newborns with any degree of PVL. This will be based upon any cranial ultrasound performed prior to discharge or transfer to another hospital.	6 months

Collaborators and Investigators

• Sponsor: University College Dublin
• Investigators: Principal Investigator: John P Kelleher, MB BCH, Coombe Women & Infants University Hospital

Publications and helpful links

General Publications

• Committee on Fetus and Newborn, Adamkin DH. Postnatal glucose homeostasis in late-preterm and term infants. Pediatrics. 2011 Mar;127(3):575-9. doi: 10.1542/peds.2010-3851. Epub 2011 Feb 28.
• Shah R, Harding J, Brown J, McKinlay C. Neonatal Glycaemia and Neurodevelopmental Outcomes: A Systematic Review and Meta-Analysis. Neonatology. 2019;115(2):116-126. doi: 10.1159/000492859. Epub 2018 Nov 8.
• Boluyt N, van Kempen A, Offringa M. Neurodevelopment after neonatal hypoglycemia: a systematic review and design of an optimal future study. Pediatrics. 2006 Jun;117(6):2231-43. doi: 10.1542/peds.2005-1919.
• Hay WW Jr. Recent observations on the regulation of fetal metabolism by glucose. J Physiol. 2006 Apr 1;572(Pt 1):17-24. doi: 10.1113/jphysiol.2006.105072. Epub 2006 Feb 2.
• Kalhan SC, D'Angelo LJ, Savin SM, Adam PA. Glucose production in pregnant women at term gestation. Sources of glucose for human fetus. J Clin Invest. 1979 Mar;63(3):388-94. doi: 10.1172/JCI109314.
• Stanley CA, Rozance PJ, Thornton PS, De Leon DD, Harris D, Haymond MW, Hussain K, Levitsky LL, Murad MH, Simmons RA, Sperling MA, Weinstein DA, White NH, Wolfsdorf JI. Re-evaluating "transitional neonatal hypoglycemia": mechanism and implications for management. J Pediatr. 2015 Jun;166(6):1520-5.e1. doi: 10.1016/j.jpeds.2015.02.045. Epub 2015 Mar 25. No abstract available.
• Thornton PS, Stanley CA, De Leon DD, Harris D, Haymond MW, Hussain K, Levitsky LL, Murad MH, Rozance PJ, Simmons RA, Sperling MA, Weinstein DA, White NH, Wolfsdorf JI; Pediatric Endocrine Society. Recommendations from the Pediatric Endocrine Society for Evaluation and Management of Persistent Hypoglycemia in Neonates, Infants, and Children. J Pediatr. 2015 Aug;167(2):238-45. doi: 10.1016/j.jpeds.2015.03.057. Epub 2015 May 6. No abstract available.

Study record dates

Study Major Dates

• Study Start (Actual): November 5, 2020
• Primary Completion (Anticipated): November 1, 2022
• Study Completion (Anticipated): December 1, 2022

Study Registration Dates

• First Submitted: December 16, 2019
• First Submitted That Met QC Criteria: April 16, 2020
• First Posted (Actual): April 20, 2020

Study Record Updates

• Last Update Posted (Actual): September 30, 2021
• Last Update Submitted That Met QC Criteria: September 29, 2021
• Last Verified: September 1, 2021

More Information

Terms related to this study

• Keywords: randomized controlled trial; placebo; Prematurity; oral dextrose gel
• Additional Relevant MeSH Terms: Glucose Metabolism Disorders; Metabolic Diseases; Hypoglycemia; Gastrointestinal Agents; Laxatives; Carboxymethylcellulose Sodium
• Other Study ID Numbers: 0062019

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No